Novavax - NVAX Price-to-Projected Revenue Ratio

Novavax, Inc. (NVAX) is optimizing costs through the robotization of filling lines, which reduces manual labor. However, the company faces regulatory pressure and competition from industry behemoths. The current focus has shifted toward influenza vaccine trials. This chart of the company's expected P/S on GURU.Markets illustrates the valuation dynamics of market capitalization relative to future revenue, where 3.40 represents the current level of the metric.

NVAX (novavax.com) Price-to-Projected Revenue Ratio history from 07/04/2022 to 11/14/2026

Novavax Pharma (NVAX) - metric breakdowns and financial figures

- market price and analyst price targets:

Price Chart Novavax|NVAX - Broker Consensus Forecast

- issuer market value details:

Market Value Novavax Pharma|NVAX - Total Enterprise Value

- book value of equity indicators:

Accounting Value per Share Novavax|NVAX - Company Book Value|Market Capitalization to Book Value Ratio novavax.com|NVAX - Company Total Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

NVAX - Net Financial Result|Expected Profit Novavax, Inc.|NVAX - Price to Earnings Multiple|Forward P/E Multiple Novavax Corp|NVAX - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Novavax Pharma|NVAX - Operating income before deduction of amortization|Earnings per share for the last twelve months Novavax|NVAX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months novavax.com|NVAX - Earnings per share growth in current year|Earnings growth forecast for next year Novavax, Inc.

- sales revenue and business income indicators:

NVAX - Revenue and Sales Volume|Company Future Sales Volume Novavax|NVAX - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio Novavax Pharma

Fundamental company analysis:Novavax (NVAX)

Forward P/S assesses the market value of an asset relative to its projected revenues, determining the extent of the premium paid for future growth. This multiple compares current market capitalization with expected revenue for the year ahead, as reflected in the trend of the expected P/S value. It is critical for investors to correlate this ratio with the business's capital intensity. For Novavax, Inc. (NVAX), a high valuation is justified by exclusive patents and stringent FDA regulatory barriers.

Competitor analysis for Novavax, Inc.

Price-to-Projected Revenue Ratio Gilead Sciences GILD|CDTX: Market Cap to Projected Revenue|CVAC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Valneva Vaccines|VIR (Vir Biotechnology, Inc.) - Forward Price-to-Revenue Multiple|SIGA (siga.com) - Price-to-Projected Revenue Ratio|EBS (Emergent BioSolutions Inc.) - Forward P/S Multiple|Forward P/S Multiple Atea Pharma|Forward Price-to-Revenue Multiple IVVD (Invivyd, Inc.)|Price-to-Projected Revenue Ratio ENTA (Enanta Pharmaceuticals, Inc)|Forward P/S Multiple INO (Inovio Pharmaceuticals)|Forward P/S Multiple hillevax.com HLVX|KLRS: Forward Price-to-Revenue Multiple|DYAI (Dyadic International) - Market Cap to Projected Revenue|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|Talphera Corporation - Forward Price to Sales|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|Traws Therapeutics (TRAW) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Dogwood Therapeutics, Inc. (DWTX)|Qualigen Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple ALVR (AlloVir)|VBIV - Forward Price-to-Revenue Multiple|VIRI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Vaxart, Inc. VXRT